China’s State FDA Approves Aoxing R&D License For Anti-Opioid Addiction Drug
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State Food and Drug Administration approved a research and development license Nov. 20 for Aoxing Pharmaceutical's opioid combo tablet buprenorphine/naloxone tailored to fight the growing problem of opioid dependence in China